OAC
CHRS icon

OMERS Administration Corp’s Coherus Oncology CHRS Stock Holding History

OMERS Administration Corp’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-23,400
Closed -$259K – 393
2018
Q1 		$259K Buy
+23,400
New +$256K ﹤0.01% 395

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OMERS Administration Corp's CHRS Position: Q2 2018 in Review

OMERS Administration Corp sold out of Coherus Oncology (CHRS) in Q2 2018, closing a stake of 23,400 shares — an estimated $259K sold.

OMERS Administration Corp first reported a position in CHRS in Q1 2018 and held it in 1 quarter. The position peaked at $259K in Q1 2018. 115 funds tracked by Wall St. Rank hold CHRS as of Q2 2018.

  • OMERS Administration Corp reported no remaining Coherus Oncology position as of Q2 2018 after selling out during the quarter.
  • OMERS Administration Corp sold 23,400 Coherus Oncology shares in Q2 2018, an estimated $259K.
  • OMERS Administration Corp first reported a position in Coherus Oncology in Q1 2018 and held it in 1 quarter.
  • OMERS Administration Corp's Coherus Oncology position peaked at $259K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2018.

Based on OMERS Administration Corp's 13F filing for Q2 2018, filed 9 Aug 2018.